Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2021 · 10-Q
Revenue$18.88M$18.88M+7.0% vs Q1 2020 Net Income-$50.14M-$50.14MN/M vs Q1 2020 EPS Diluted-$1.20-$1.20N/M vs Q1 2020 Operating Income-$44,042,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$75,068,000N/M Margins · derivedOperating margin-233.2%−19.6 pt vs Q1 2020
Net margin-265.5%−38.6 pt vs Q1 2020
ended Mar 31, 2021 · filed May 5, 2021 · 35 d after period end